Benzinga · Sep 10, 2026
HSBC Maintains Reduce on Biogen, Raises Price Target to $175
HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.
NASDAQ · BIIB
Biogen Inc.
Healthcare · Drug Manufacturers - General
$216.17
Down-$1.19 (-0.55%)
Updated Sep 16, 2026, 4:38 AM
SID Score
7.0/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 25.33B
- P/E ratio
- 15.74
- Dividend yield
- 0.00%
- 52-week range
- $160.36 – $225.80
- Volume
- 756.05K
- Avg. volume
- 1.8M
Price performance
BIIB price history
1M range · 20 trading sessions · Daily adjusted prices
BIIB closed at $216.17 after 20 trading sessions, up 1.70% for the selected period.
- Last close
- $216.17
- Period change
- +1.70%
- Period low
- $210.73
- Period high
- $224.51
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $216.71 | $216.71 | $213.54 | $216.17 | 756.05K |
| Sep 14, 2026 | $221.00 | $222.245 | $215.56 | $217.36 | 629.93K |
| Sep 11, 2026 | $216.75 | $219.76 | $214.7125 | $217.15 | 1.08M |
| Sep 10, 2026 | $209.92 | $216.70 | $208.9279 | $215.43 | 936.64K |
| Sep 9, 2026 | $210.50 | $213.48 | $209.00 | $210.73 | 694.67K |
| Sep 8, 2026 | $215.45 | $217.2803 | $210.54 | $212.50 | 617.83K |
| Sep 4, 2026 | $221.15 | $223.82 | $219.82 | $220.83 | 465.11K |
| Sep 3, 2026 | $225.44 | $225.80 | $221.23 | $224.51 | 550.75K |
| Sep 2, 2026 | $218.20 | $225.59 | $216.97 | $222.67 | 1.27M |
| Sep 1, 2026 | $218.11 | $219.30 | $213.60 | $216.04 | 785.5K |
| Aug 31, 2026 | $216.47 | $218.89 | $213.58 | $216.65 | 831K |
| Aug 28, 2026 | $221.17 | $222.00 | $216.78 | $218.50 | 517.48K |
| Aug 27, 2026 | $219.39 | $222.11 | $217.53 | $221.50 | 497.52K |
| Aug 26, 2026 | $219.34 | $222.00 | $218.6907 | $221.07 | 647.33K |
| Aug 25, 2026 | $218.93 | $222.85 | $218.00 | $220.77 | 495.44K |
| Aug 24, 2026 | $216.40 | $218.50 | $213.96 | $218.12 | 649.83K |
| Aug 21, 2026 | $217.76 | $219.12 | $215.00 | $216.78 | 722.35K |
| Aug 20, 2026 | $217.98 | $221.29 | $214.16 | $214.35 | 808.63K |
| Aug 19, 2026 | $215.33 | $222.15 | $215.075 | $221.56 | 886.91K |
| Aug 18, 2026 | $211.00 | $214.065 | $210.01 | $212.55 | 694.01K |
Latest BIIB news
The latest Smart Investors Daily articles mentioning BIIB.
Stock researchCompany · Overview
BIIB research
Overview
Company profile and research snapshot.
Company profile
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $177.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Reduce | — |
| Sep 3, 2026 | Piper Sandler | Overweight | — |
| Aug 25, 2026 | RBC Capital | Outperform | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Aug 4, 2026 | Mizuho | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Biogen Inc. (BIIB) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 9:30 AM EDTCompany ParticipantsRobin Kramer - Executive VP & CFOAdam...
CNBC · Sep 9, 2026
Biogen CEO: We are at that inflection point where we are on a path to sustainable revenue growth
Biogen CEO Christopher Viehbacher joins 'Squawk on the Street' to discuss their upcoming product pipeline, developments in Alzheimer treatment and medication and more.
Yahoo · Sep 8, 2026
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit
FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encouraged to secure their seats now while limited seating remains available. The September 10 summit at The Harvard Club of Boston will bring together CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology leaders to discuss AI governance, Agen
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
